Physician profile
Samir Samarany
NPI 1134379126
$19,634.85
in general payments reported to CMS, 2019-2025
44 companies · $4,553 in 2025
The $4,553 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $1,827 · 2021: $1,521 · 2022: $1,898 · 2023: $1,997 · 2024: $7,021 · 2025: $4,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,284 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,250 · Education: $21.70 · Entertainment: $15.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,284.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,250.00 |
| Education | $21.70 |
| Entertainment | $15.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,863.93 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $2,143.08 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $1,549.37 | 2020-2025 | General - Brady, Avvigo Guidance System, Varithena Administration Pack |
| Abbott Laboratories | $1,062.26 | 2019-2025 | Mitraclip, Amplatzer Talisman |
| Edwards Lifesciences Corporation | $892.12 | 2022-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $844.10 | 2021-2025 | Verquvo, Winrevair |
| Abiomed | $721.92 | 2022-2025 | Impella |
| Amgen INC. | $706.42 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $458.29 | 2019-2025 | |
| Cardiovascular Systems INC. | $428.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $378.60 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.61 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $295.09 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $266.53 | 2021-2024 | Amvuttra, Onpattro |
| Acutus Medical, INC. | $210.29 | 2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Samarany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.